Robert Whitfield MDAmerica's Breast Implant Illness Expert™

Genetic Therapeutics: $4.3 Trillion Industry by 2030! #shorts

19 Apr 2026 · 1 min

Watch on YouTube

1:17

In this short discussion, two speakers highlight the rapidly expanding field of genetic therapeutics, citing a Goldman Sachs forecast that the market will reach $4.3 trillion by 2030. Speaker A emphasizes the elegance of targeting single genes to prevent or treat disease—shutting off harmful genes that contribute to conditions like breast cancer, or up‑regulating protective genes to reduce inflammation and improve organ resilience. He suggests that such gene‑modulating drugs could eventually provide simple, pill‑ or injection‑based solutions for complex disorders, even Alzheimer’s. Speaker B shifts focus to regenerative medicine, arguing that the pinnacle of therapy is autologous stem‑cell treatment; after three decades of surgical practice, he trusts his own cells over donor cells, asserting that no other product can match the value of a patient’s own stem cells.

Chapters

Now, genetic therapeutics. I think Goldman Sachs said that by 2030, genetic therapeutics are going to be a $4.3 trillion industry. So that's what I'm excited about. Not for some of the nefarious stuff that might be out there, but just the simple ease and elegance of you make a toxic hormone that ends up in your fatty tissue that could create breast cancer. Let's shut that gene off. You don't build tissue quality in the endothelium or in the kidney or in the liver, the actual physical structure of the organ isn't so resilient. Let's upregulate that gene so the tissue is less prone to inflammation. So, solving the functional issues and with a simple therapeutic that just keeps a gene upregulated, the expression is higher so it's doing the job better. So, I think we've been working on the targets. Now, there's the therapies and sort of tools that we didn't have. And, I think that's going to lead to literally How do we shut off Alzheimer's? Take a pill, take an injection. It's going to get to that.
Uh, we should have, and really everybody clamors for the top of the pyramid is stem cell therapy. But if you're someone like me who's operated for almost 30 years now, you know the value of your own cells over anybody else's cells. So there is no other product at the top of the pyramid outside of your own stem cells.